eGenesis

eGenesis

A Cambridge, MA - based startup that uses gene editing tech for xenotransplantation procedures in the medical industry.

In August 2018 eGenesis has disclosed $40m in funding by ARCH Venture Partners, Biomatics Capital Partners, Khosla Ventures, and Fan Ventures.

eGenesis' stated goal is to make xenotransplantation a routine medical procedure. The company is a Cambridge, MA-based startup that's using the gene-editing tool CRISPR to make pig organs viable for transplants into people.

The company raised $38 million in March 2017 and is cofounded by Harvard geneticist George Church and Luhan Yang. Their research is focusing on removing certain genes in pigs that could cause diseases or organ rejection in humans, making it possible for those pig organs to be transplanted. eGenesis announced in the journal Science that it had produced 37 piglets that had inactivated Porcine Endogenous Retrovirus, or PERV.

eGenesis scientists collaborated with scientists at QihanBio in Hangzhou, China on research that combined PERV knockouts with 13 other genetic changes designed to prevent immune rejection. Lead author on the research paper published in 2019 in BioRxriv is eGenesis’ Chief Scientific Officer, Luhan Yang, who is also CEO of QihanBio. Modifications were done in pig ear cells. The pig ear cells were used to generate pig clones. The nuclei of the ear cells, containing the modified DNA, were transferred into eggs from ovaries collected at a slaughterhouse. A second round of editing was used to remove PERV sequences followed by another round of cloning by transferring nuclei to eggs.

Timeline

November 5, 2020
eGenesis announces research collaboration with leading academic medical Center.

November 2019
eGenesis raises a $100,000,000 series B round from ARCH Venture Partners, Alta Partners, Bayer, Biomatics Capital Partners, Fresenius Medical Care, Khosla Ventures and Wellington Partners.
March 2017
eGenesis raises a $38,189,826 series A round from ARCH Venture Partners, Alexandria Venture Investments, Alta Partners, Berggruen Holdings, Biomatics Capital Partners, Heritage Provider Network, Khosla Ventures and Uprising.
2015
eGenesis was founded by George Church and Luhan Yang.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
eGenesis, Inc. funding round, March 2017
38,189,826
March 2017
4 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

George Church

Co-founder

Luhan Yang

Co-founder, CSO

Further reading

Title
Author
Link
Type
Date

Eyeing organs for human transplants, companies unveil the most extensively gene-edited pigs yet

Web

December 19, 2019

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
AlleyWatch
March 7, 2021
AlleyWatch
The Pulse of New York Tech
Eudora Wang
March 4, 2021
DealStreetAsia
eGenesis was created in 2015 by George Church and Yang, who also launched China's Qihan Biotech in 2017.
Conor Hale
November 6, 2020
FierceBiotech
EGenesis has announced a research collaboration with Duke University's school of medicine to help develop its xenotransplantation technology into a cell therapy for diabetes.
BioSpace
November 5, 2020
BioSpace
eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, today announced the initiation of a research collaboration with Duke University School of Medicine. The collaboration will encompass evaluation of gene-edited pancreatic islet cells in non-human primate recipients as a prerequisite to advancin
Alex Keown
May 20, 2020
BioSpace
Xenotransplant company eGenesis snapped up a key manufacturing partner ICBiotec in order to vertically integrate its xeno-organ production capabilities.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.